Markets & Stocks
OCT Announces 2nd Clinical Trial, Chill Brands Investor Calls For Director Ousting, & More From SEED
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”line” assets=”OCTP.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a second compound after partnering with Australian contract research organisation (CRO) iNGENū.
